Geographic Area
AstraZeneca Pays $1.2B Upfront in $18.5B Deal for CSPC’s Long-Acting Obesity Drugs
AstraZeneca; CSPC; obesity drugs; weight loss; licensing deal; China; GLP1RA
AstraZeneca Announces $15 Billion Investment in China Through 2030
AstraZeneca; China; $15B investment; drug R&D; cell therapy; manufacturing; Keir Starmer
Formation Bio Eyes Abivax-Like Success with Chinese Drug Licensing Deal Targeting Same Mechanism
Formation Bio; Abivax; licensing deal; China; cancer drug; PD-1/VEGF; biotech
Hua Medicine Advances Dorzagliatin Expansion Beyond China with Hong Kong NDA Acceptance
Hua Medicine; dorzagliatin; diabetes drug; China expansion; Hong Kong NDA; Southeast Asia; glucokinase activator
Orphan Drug Trends: A Data-Driven Analysis
orphan drugs; market growth; rare diseases; FDA approvals; genomics; reimbursement challenges
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Makary Proposes Higher FDA User Fees for Non-US Phase I Trials to Counter China Biotech
Makary; FDA; user fees; China; biotech; Phase I trials; America First
Nxera Pharma Reports Positive Phase 3 Results for Daridorexant in South Korea Insomnia Trial
Nxera Pharma; daridorexant; Phase 3; insomnia; South Korea; QUVIVIQ
Novo Nordisk Foundation Commits Over $850M to Danish Life Science Incubator BII Over Next Decade
Novo Nordisk Foundation; BII; life science incubator; $850M; biotech startups; Denmark
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech